呋塞米联合左西孟旦对顽固性心力衰竭患者心功能和N端B型利钠肽原的影响

Effect of furosemide combined with levosimendan on cardiac function and N-terminal B-type natriuretic peptide in patients with refractory heart failure

  • 摘要: 目的 探讨呋塞米联合左西孟旦对顽固性心力衰竭患者心功能和N端B型利钠肽原(NT-proBNP)的影响。 方法 将80例顽固性心力衰竭患者随机分为实验组和对照组,每组40例。对照组采用呋塞米治疗,实验组采用左西孟旦联合呋塞米治疗。比较2组心功能指标、炎症因子水平及临床疗效。 结果 治疗后,实验组NT-proBNP、血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)水平均低于对照组,差异有统计学意义(P<0.05); 左心室射血分数(LVEF)和每搏输出量(SV)均高于对照组,差异有统计学意义(P<0.05); 实验组总有效率为80.00%, 高于对照组的57.50%, 差异有统计学意义(P<0.05)。 结论 采用呋塞米联合左西孟旦可显著改善顽固性心力衰竭患者心功能,减轻炎症反应。

     

    Abstract: Objective To investigate the effect of furosemide combined with levosimendan on cardiac function and N-terminal B-type natriuretic peptide(NT-proBNP)in patients with refractory heart failure. Methods A total of 80 patients with refractory heart failure were randomly divided into experimental group and control group, with 40 cases in each group. The control group was treated with furosemide, while the experimental group was treated with levosimendan combined with furosemide. Cardiac function index, inflammatory factor and clinical efficacy were compared between the two groups. Results After treatment, NT-proBNP, serum hypersensitive C-reactive protein(hS-CRP)and the levels of interleukin-6(IL-6)in the experimental group were significantly lower than those in the control group(P<0.05); left ventricular ejection fraction(LVEF)and stroke volume(SV)were significantly higher than those in the control group(P<0.05). The total effective rate of the experimental group was 80.00%, which was significantly higher than 57.50% of the control group(P<0.05). Conclusion The treatment of refractory heart failure with furosemide combined with levosimendan can significantly improve the heart function, and reduce the inflammatory response in patients with refractory heart failure.

     

/

返回文章
返回